Induction of withdrawal-like symptoms in a small randomized, controlled trial of opioid blockade in frequent tanners

      Frequent tanning has reinforcing properties. We tested whether opioid antagonism blocks potential reinforcing effect of indoor tanning in 8 frequent tanners and 8 infrequent tanner control subjects. Opioid blockade reduced ultraviolet preference in frequent tanners. Four of 8 frequent tanners, but no infrequent tanners, exhibited withdrawal-like symptoms with naltrexone administration. A limitation of this study is its small size.
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Feldman S.R.
        • Liguori A.
        • Kucenic M.
        • Rapp S.R.
        • Fleischer A.B.
        • Lang W.
        • et al.
        UV exposure is a reinforcing stimulus in frequent indoor tanners.
        J Am Acad Dermatol. 2004; 51: 45-51
      1. Scerra C. Addicted to the sun? Dermatology Times, September 1, 2003. Available at: Accessed January 18, 2006.

        • Levins P.C.
        • Carr D.B.
        • Fisher J.E.
        • Momtaz K.
        • Parrish J.A.
        Plasma beta-endorphin and beta-lipoprotein response to ultraviolet radiation.
        Lancet. 1983; 2 ([letter]): 166
        • Kaur M.
        • Liguori A.
        • Fleischer A.B.
        • Feldman S.
        Side effects of naltrexone observed in 2 of 3 frequent tanners: Could frequent tanners have chronically high opioid levels?.
        J Am Acad Dermatol. 2005; 52: 916
        • Perez-Reyes M.
        • Wall M.E.
        A comparative study of the oral, intravenous, and subcutaneous administration of H-Naltrexone to normal male volunteers. Naltrexone: Research Monograph 28.
        in: Willette R.E. Barnett G. National Institute on Drug Abuse, Bethesda (MD)1980: 93-101 (Available at: Accessed January 18, 2006)
        • Gonzalez J.P.
        • Brogden R.N.
        Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.
        Drugs. 1988; 35: 192-213